NCT02664883Active, not recruiting
Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer
MDSC Clinical Assay for Cancer Detection and Monitoring in Renal Cell Carcinoma
Source: ClinicalTrials.gov · Last updated 2 Apr 2026
Brief summary (registry, in English)
This pilot research trial studies the use of the Myeloid Derived Suppressor Cells Clinical Assay in finding and monitoring kidney cancer. Studying samples of blood and urine from patients with kidney cancer in the laboratory may aid doctors in the early detection of cancer, monitor tumor response to therapy, detect the presence of occult spreading of disease, and identify early return of disease.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 37 (actual)
- First submitted
- 22 Jan 2016
- Start date
- 8 Sept 2015
- Primary completion date
- 13 Apr 2022
- Lead sponsor
- University of Southern California
- Diseases
- Kidney cancer
- NCT number
- NCT02664883
What you commit to
- Study type: Observational
- Participants enrolled: 37
- From 8 Sept 2015 to the primary completion date, 13 Apr 2022
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- For localized RCC arm: no evidence of metastatic disease, second cancer, prior chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
- For metastatic RCC arm: no evidence of second cancer, prior chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
Other illness
- For normal subject arm: no evidence of cancer or hematuria
- For all subjects: uncontrolled intercurrent illness including, but not limited to previous or current history of second malignancy unrelated to renal cell carcinoma; autoimmune disease or immune deficiency, chronic treatment with immunomodulatory therapies (e.g. glucocorticoids); significant trauma, surgery, or infection in the past two weeks or psychiatric illness/social situations that would limit compliance with study requirements
Who the study is looking for
- Subjects enrolled in this study must meet one of the 3 following criteria:
- Group 1: Healthy individual with no history of cancer or hematuria
- Group 2: Subject with a diagnosis of localized renal cell carcinoma (by imaging and eventual pathology) scheduled to undergo nephrectomy
- Group 3: Subject with a diagnosis of metastatic renal cell cancer(by imaging and eventual pathology) who is scheduled to begin a new systemic therapy
- Any type of renal cell carcinoma (RCC); any prior therapy
- Performance status: 0-3
- Leukocytes \>= 3,000/mcL (frequently used - numbers listed are examples, investigator should modify as needed)
- Absolute neutrophil count \>= 1,500/mcL (frequently used - numbers listed are examples, investigator should modify as needed)
- Ability to understand and the willingness to sign a written informed consent
Age in the registry: 25 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| USC / Norris Comprehensive Cancer Center Coordinator of this site? Confirm its status | Los Angeles | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.